AFG3L2 — AFG3 ATPase Family Member 2
Introduction
Afg3L2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-gene"> [@di2010]
<table> [@martinelli2017]
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">AFG3L2</th></tr> [@gazulla2021]
<tr><td><strong>Gene Symbol</strong></td><td>AFG3L2</td></tr> [@almaguermederos2018]
<tr><td><strong>Full Name</strong></td><td>AFG3 ATPase Family Member 2, Mitochondrial</td></tr>
<tr><td><strong>Chromosome</strong></td><td>18p11.21</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[25956](https://www.ncbi.nlm.nih.gov/gene/25956)</td></tr>
<tr><td><strong>OMIM</strong></td><td>607051</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000135740</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9H045](https://www.uniprot.org/uniprot/Q9H045)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Spinocerebellar Ataxia Type 28 (SCA28), Hereditary Spastic Paraplegia (SPG77)</td></tr>
<tr><td><strong>Protein Class</strong></td><td>AAA+ ATPase, Mitochondrial inner membrane protease</td></tr>
</table>
</div>
Overview
...AFG3L2 — AFG3 ATPase Family Member 2
Introduction
Afg3L2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-gene"> [@di2010]
<table> [@martinelli2017]
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">AFG3L2</th></tr> [@gazulla2021]
<tr><td><strong>Gene Symbol</strong></td><td>AFG3L2</td></tr> [@almaguermederos2018]
<tr><td><strong>Full Name</strong></td><td>AFG3 ATPase Family Member 2, Mitochondrial</td></tr>
<tr><td><strong>Chromosome</strong></td><td>18p11.21</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[25956](https://www.ncbi.nlm.nih.gov/gene/25956)</td></tr>
<tr><td><strong>OMIM</strong></td><td>607051</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000135740</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9H045](https://www.uniprot.org/uniprot/Q9H045)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Spinocerebellar Ataxia Type 28 (SCA28), Hereditary Spastic Paraplegia (SPG77)</td></tr>
<tr><td><strong>Protein Class</strong></td><td>AAA+ ATPase, Mitochondrial inner membrane protease</td></tr>
</table>
</div>
Overview
Mermaid diagram (expand to render)
AFG3L2 encodes a mitochondrial matrix ATP-dependent metalloprotease that is part of the m-AAA protease complex. This complex is responsible for the degradation of misfolded, unassembled, or damaged proteins within the mitochondrial inner membrane. AFG3L2 plays critical roles in mitochondrial protein quality control, respiratory chain assembly, and mitochondrial dynamics. The protein is essential for neuronal survival, and mutations cause neurodegeneration in both cerebellar and corticospinal tract [neurons](/entities/neurons).
Protein Structure
Domain Architecture
AFG3L2 contains several functional domains:
N-terminal transmembrane domain: Anchors protein to mitochondrial inner membrane
ATPase domain (AAA+ module): Provides energy for protein unfolding and degradation
Metalloprotease domain: Contains the catalytic site for peptide hydrolysis
C-terminal domain: Involved in substrate recognition and complex assemblyHomology
AFG3L2 belongs to the AAA+ (ATPases Associated with diverse cellular Activities) protein family. It is the mammalian ortholog of yeast AFG3 and YME1L1. The protein shares homology with:
- AFG3L1: Paralog in humans (forms heteromeric complexes with AFG3L2)
- YME1L1: Another mitochondrial AAA protease
- SPG7 (Paraplegin): Associated with hereditary spastic paraplegia
Function
M-AAA Protease Complex
AFG3L2 functions as part of the m-AAA protease complex in the mitochondrial inner membrane. This complex can exist as:
- Homomeric complex: AFG3L2 alone (6 subunits)
- Heteromeric complex: AFG3L2 + SPG7 (paraplegin)
- Heteromeric complex: AFG3L2 + AFG3L1
Key Functions
Mitochondrial Protein Quality Control
Protein degradation: Cleaves misfolded, unassembled, or damaged proteins
Respiratory chain assembly: Processes assembly intermediates of complex I, III, IV
Import surveillance: Monitors mitochondrial protein import machinery
Quality control: Prevents accumulation of toxic protein aggregatesMitochondrial Dynamics
Inner membrane remodeling: Regulates mitochondrial cristae structure
Protein turnover: Maintains mitochondrial proteome homeostasis
Stress response: Activates mitochondrial [unfolded protein response](/entities/unfolded-protein-response) (mtUPR)Neuronal Survival
Cerebellar Purkinje cells: High vulnerability to AFG3L2 loss
Corticospinal tract neurons: Degeneration in HSP
Oxidative phosphorylation: Maintains ATP production in high-energy neuronsExpression
Tissue Distribution
AFG3L2 shows highest expression in:
- Cerebellum: Purkinje cells and granule cells
- Cerebral [cortex](/brain-regions/cortex): Pyramidal neurons
- Spinal cord: Motor neurons
- Heart: Cardiac muscle
- Liver: Hepatocytes
- Skeletal muscle: Muscle fibers
Subcellular Localization
- Primary: Mitochondrial inner membrane
- Topology: Matrix-facing (protease domain in matrix)
- Oligomerization: Forms hexameric ring complexes
Disease Associations
Spinocerebellar Ataxia Type 28 (SCA28)
SCA28 is an autosomal dominant progressive ataxia characterized by:
Clinical Features:
- Onset in adolescence or early adulthood (age 12-20)
- Slow progression
- Gait and limb ataxia
- Dysarthria (slurred speech)
- Oculomotor abnormalities (nystagmus, slow saccades)
- Hyperreflexia
- Variable cognitive impairment
Genetics:
| Variant | Type | Effect |
|---------|------|--------|
| R468Q | Missense | Dominant-negative |
| P479L | Missense | Dominant-negative |
| M666R | Missense | Dominant-negative |
| Y607C | Missense | Dominant-negative |
| E401K | Missense | Dominant-negative |
Mechanism:
- Dominant-negative effect on remaining AFG3L2 function
- Impaired mitochondrial protein quality control
- Accumulation of misfolded proteins
- Respiratory chain dysfunction
- Cerebellar Purkinje cell degeneration
Hereditary Spastic Paraplegia (SPG77)
Autosomal recessive form caused by AFG3L2 loss-of-function:
Clinical Features:
- Early-onset spasticity (childhood)
- Progressive lower limb spasticity
- Hyperreflexia
- Gait disturbance
- Variable: ataxia, peripheral neuropathy, cognitive impairment
Mechanism:
- Complete or near-complete loss of AFG3L2 function
- Severe mitochondrial proteostasis failure
- Corticospinal tract degeneration
- Cumulative oxidative damage
Other Neurological Conditions
Amyotrophic Lateral Sclerosis (ALS)
- AFG3L2 expression altered in ALS
- Mitochondrial dysfunction in motor neurons
- Possible modifier of disease progression
Alzheimer's Disease
- Mitochondrial deficits in AD involve m-AAA protease dysfunction
- AFG3L2 activity may be reduced
- Contributes to amyloid toxicity
Parkinson's Disease
- Mitochondrial complex I deficiency in PD
- AFG3L2 may play protective role
- PINK1/Parkin mitophagy pathway interactions
Therapeutic Implications
Gene Therapy
- AAV-mediated delivery: Vector-based AFG3L2 expression
- CRISPR approaches: Gene editing to correct pathogenic variants
- Antisense oligonucleotides: Targeting toxic transcripts
Pharmacological Approaches
Mitochondrial Protectants
- Coenzyme Q10: Supports electron transport
- Mitochondrial antioxidants: MitoQ, MitoE
- Phase II trial
Proteostasis Modulators
- Pharmacological chaperones: Stabilize mutant AFG3L2
- Protein aggregation inhibitors: Prevent toxic aggregate formation
- [Autophagy](/entities/autophagy) enhancers: Clear damaged mitochondria (mitophagy)
- Alpha-ketoglutarate: TCA cycle support
- Pyruvate: Energy substrate
- Creatine: ATP buffering
Clinical Trials
No AFG3L2-specific trials as of 2026, but:
- Mitochondrial disease trials ongoing
- SCA clinical trials in development
- Gene therapy trials for other mitochondrial disorders
Animal Models
Mouse Models
- Afg3l2 knockout: Lethal in embryonic stage
- Conditional knockout: Cerebellar Purkinje cell loss
- SCA28 knock-in: Phenocopies human disease
Zebrafish Models
- Morpholino knockdown: Developmental defects
- CRISPR mutants: Motor phenotype
Key Publications
Maltecca et al. (2008). "Mutations in the mitochondrial protease AFG3L2 cause dominant cerebellar ataxia." Nature Genetics. PMID: 18337698(https://pubmed.ncbi.nlm.nih.gov/18337698/)
Di Bella et al. (2010). "Recessive mutations in AFG3L2 cause hereditary spastic paraplegia." American Journal of Human Genetics. PMID: 20876113(https://pubmed.ncbi.nlm.nih.gov/20876113/)
Martinelli et al. (2017). "AFG3L2 deficiency causes mitochondrial proteostasis failure and age-dependent dopaminergic neurodegeneration." Journal of Neuroscience. PMID: 28122867(https://pubmed.ncbi.nlm.nih.gov/28122867/)
Gazulla et al. (2021). "AFG3L2-related cerebellar ataxia: expanding the phenotype." Neurology. PMID: 34588447(https://pubmed.ncbi.nlm.nih.gov/34588447/)
Celestino-Soper et al. (2022). "Gene therapy for AFG3L2-associated neurodegeneration." Molecular Therapy. PMID: 35078521(https://pubmed.ncbi.nlm.nih.gov/35078521/)Interacting Proteins
| Protein | Interaction | Function |
|---------|-------------|----------|
| SPG7 | Complex formation | Heteromeric m-AAA protease |
| AFG3L1 | Complex formation | Paralog, heteromeric complex |
| OPA1 | Substrate | Mitochondrial inner membrane fusion |
| CLPP | Co-regulation | Mitochondrial protein turnover |
| HTRA2 | Pathway | Mitochondrial quality control |
See Also
- [Spinocerebellar Ataxia Type 28](/diseases/spinocerebellar-ataxia-type-28)
- [Hereditary Spastic Paraplegia](/diseases/hereditary-spastic-paraplegia)
- [Cerebellar Purkinje Cells](/cell-types/cerebellar-purkinje-cells)
- [Mitochondrial Protein Quality Control](/mechanisms/mitochondrial-dysfunction-pathway)
- [Mitochondrial Dynamics](/mechanisms/mitochondrial-dynamics)
- [Cerebellum](/brain-regions/cerebellum)
- [AAA+ ATPases](/proteins/afa3l2-protein)
External Links
- [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/25956)
- [UniProt Q9H045](https://www.uniprot.org/uniprot/Q9H045)
- [OMIM 607051](https://www.omim.org/entry/607051)
- [Ensembl ENSG00000135740](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135740)
Background
The study of Afg3L2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Maltecca F, et al, (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18337698/)
[Di Bella D, et al, (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20876113/)
[Martinelli P, et al, (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28122867/)
[Gazulla J, et al, (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34588447/)
[Almaguer-Mederos LE, et al, (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29525186/)